Advances in the neurobiology of alcoholism have led to the investigation of medications or its treatment. Simultaneously, investigation of psychosocial interventions utilizing sound scientific clinical trial methodologies have occurred. The intersection of these events has led to the examination of alcoholism treatments which combine psychosocial treatment with phamacotherapy. Currently our group is evaluating the efficacy of the opiate antagonist medication naltrexone combined with 12 weekly sessions of Cognitive Behavioral Therapy (CBT) for outpatient alcoholics. This treatment shows evidence of high rates of completion and compliance. This continuation proposal will compare CET (12 sessions) with a more time limited (4 sessions) Motivational Enhancement Therapy to which naltrexone or placebo medication is added. In this randomized clinical trial 160 alcohol dependent outpatients, after 5 days of abstinence, will receive one of the two psychosocial therapies and either naltrexone or placebo over a 12 week treatment period. Abstinence rates, alcohol use, and time to alcohol relapse will be evaluated in all four group along with measures of alcohol craving, biological measures of alcohol consumption (CDT and GGT), drinking consequences, changes in self-efficacy for avoiding alcohol, and medication compliance (urinary riboflavin maker). All study participants will be assessed at 3 and 6 months after completing the treatment protocol utilizing the same outcome variables. Therapy will be provided by trained therapists according to manuals produced during Project MATCH, the large multi-site psychotherapy study in which our center participated. Quality control of therapy will be achieved by direct supervision and rating of random therapy tapes. State-of-the-art alcohol and craving assessment instruments, biologic markers, and compliance measures will be utilized to assess outcome to treatment. Results of this trial should allow evaluation of whether less intense, and potentially less costly, therapies with good patient acceptance could, when combined with efficacious medication, have equivalent results with a proven more intensive and skill requiring approach. As such, these results will provide data regarding the types of treatment likely to benefit outpatient alcoholics when applied in other health care settings where issues of clinical acceptability and cost might be consideration.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
5R01AA009568-09
Application #
6168270
Study Section
Health Services Research Review Subcommittee (AA)
Program Officer
Fertig, Joanne
Project Start
1992-09-30
Project End
2002-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
9
Fiscal Year
2000
Total Cost
$360,887
Indirect Cost
Name
Medical University of South Carolina
Department
Psychiatry
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Adams, Zachary W; Schacht, Joseph P; Randall, Patrick et al. (2016) The Reasons for Heavy Drinking Questionnaire: Factor Structure and Validity in Alcohol-Dependent Adults Involved in Clinical Trials. J Stud Alcohol Drugs 77:354-61
Anton, Raymond F; Myrick, Hugh; Wright, Tara M et al. (2011) Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 168:709-17
Baros, A M; Wright, T M; Latham, P K et al. (2008) Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. Alcohol Alcohol 43:192-7
Baros, A M; Latham, P K; Anton, R F (2008) Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res 32:771-6
Baros, Alicia M; Latham, Patricia K; Moak, Darlene H et al. (2007) What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 31:596-603
Anton, Raymond F; Moak, Darlene H; Latham, Patricia et al. (2005) Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 25:349-57
Anton, R F (2001) Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 62 Suppl 20:11-7
Anton, R F (2001) Carbohydrate-deficient transferrin for detection and monitoring of sustained heavy drinking. What have we learned? Where do we go from here? Alcohol 25:185-8
Anton, R F (2000) Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction 95 Suppl 2:S211-7
Horner, M D; Waid, L R; Johnson, D E et al. (1999) The relationship of cognitive functioning to amount of recent and lifetime alcohol consumption in outpatient alcoholics. Addict Behav 24:449-53

Showing the most recent 10 out of 21 publications